WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 584934
CAS#: 55689-65-1
Description: Oxepinac is a non-steroidal anti-inflammatory drug.
MedKoo Cat#: 584934
Name: Oxepinac
CAS#: 55689-65-1
Chemical Formula: C16H12O4
Exact Mass: 268.0736
Molecular Weight: 268.268
Elemental Analysis: C, 71.64; H, 4.51; O, 23.86
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Oxepinac; Oxepinaco; Oxepinacum
IUPAC/Chemical Name: 6,11-Dihydro-11-oxodibenz(b,e)oxepin-3-acetic acid
InChi Key: PYIHCGFQQSKYBO-UHFFFAOYSA-N
InChi Code: InChI=1S/C16H12O4/c17-15(18)8-10-5-6-13-14(7-10)20-9-11-3-1-2-4-12(11)16(13)19/h1-7H,8-9H2,(H,17,18)
SMILES Code: O=C(O)CC1=CC=C2C(OCC3=CC=CC=C3C2=O)=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 268.268 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Kojima H, Hashizume T, Chiba T, Tanaka M, Kasai Y, Kasahara A. General pharmacology of oxepinac. Arzneimittelforschung. 1978;28(3):439-45. PubMed PMID: 580753.
2: Arauchi T, Watanabe T, Nakashima K, Matsuhashi K, Morita H, Akimoto T. Teratogenicity study of oxepinac in mice and rabbits. Arzneimittelforschung. 1978;28(3):451-5. PubMed PMID: 580755.
3: Nomura M, Onodera T, Kato M, Yamada A, Ogawa H, Akimoto T. Acute, subacute and chronic toxicity of oxepinac. Arzneimittelforschung. 1978;28(3):445-51. PubMed PMID: 580754.
4: Hakusui H, Suzuki W, Takegoshi T, Saito T, Sano M. Studies on pharmacokinetics and biotransformation of oxepinac in mouse, rat, dog and man. Arzneimittelforschung. 1978;28(3):456-61. PubMed PMID: 580756.
5: Sasaki S. Multi-centered clinical evaluation of oxepinac against peripheral arthropathy particularly osteoarthritis. Arzneimittelforschung. 1978;28(3):462-8. PubMed PMID: 350232.
6: Hakusui H, Suzuki W, Sano M. Quantitative analysis of oxepinac in human plasma, urine and saliva by gas chromatography--mass fragmentography. J Chromatogr. 1980 Apr 11;182(1):47-53. PubMed PMID: 7380901.
7: Tsukada W, Tsubokawa M, Masukawa T, Kojima H, Kasahara A. Pharmacological study of 6,11-dihydro-11-oxodibenz[b,e]oxepin-3-acetic acid (oxepinac): a new antiinflammatory drug. Arzneimittelforschung. 1978;28(3):428-38. PubMed PMID: 580752.
8: Tagawa H, Kubo S. Nonsteroidal antiinflammatory agents. V. Photolysis of 6,11-dihydro-11-oxodibenz[b,e]oxepin-3-acetic acid. Chem Pharm Bull (Tokyo). 1984 Aug;32(8):3047-52. PubMed PMID: 6518586.
